PR004 / Eli Lilly - LARVOL DELTA

Eli Lilly Snaps Up Gene Therapy Company Prevail Therapeutics in $1.04 Billion Deal (BioSpace) - "Shares of Prevail Therapeutics have skyrocketed more than 84% in premarket trading after Eli Lilly announced it was acquiring the gene therapy company in a deal valued at approximately $1.04 billion. Since the deal was announced, Prevail’s stock has nearly doubled to $23 per share, higher than the tender offer of $22.50."

M&A • Stock price • CNS Disorders • Frontotemporal Lobar Degeneration • Parkinson's Disease • Tauopathies And Synucleinopathies

Lilly Announces Agreement to Acquire Prevail Therapeutics (Prevail Therapeutics Press Release) - "Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement for Lilly to acquire Prevail...The CVR is payable (subject to certain terms and conditions) upon the first regulatory approval of a product from Prevail's pipeline....Prevail's lead gene therapies in clinical development are PR001 for patients with Parkinson's disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD) and PR006 for patients with frontotemporal dementia with GRN mutations (FTD-GRN). Prevail's preclinical pipeline includes PR004 for patients with specific synucleinopathies, as well as potential gene therapies for Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders."

M&A • CNS Disorders • Frontotemporal Lobar Degeneration • Parkinson's Disease • Tauopathies And Synucleinopathies